Core Viewpoint - McKesson Corporation (NYSE:MCK) is recognized as a promising investment opportunity, particularly due to its recent developments in the biosimilar market and the potential for significant growth in this sector [2][3]. Group 1: Investment Recommendations - Bank of America has raised its price target for McKesson Corporation from $970 to $1,040, maintaining a Buy rating on the shares [2]. - The firm believes that the market may be underestimating the potential of several large biosimilars expected to launch in the coming years, with seven anticipated, four of which McKesson could directly address [3]. Group 2: Company Overview - McKesson Corporation is a diversified healthcare services company focused on improving health outcomes for patients, distributing a wide range of pharmaceutical products across the United States [4].